Background: Cardiac resynchronization therapy (CRT) is an effective treatment for patients with heart failure; however, 30% of patients do not respond to the treatment. We sought to derive patient-specific left-ventricle (LV) maps of lead placement scores (LPS) that highlight target pacing lead sites for achieving a higher probability of CRT response. Methods: Eighty-two subjects recruited for the ImagingCRT trial were retrospectively analyzed. All 82 subjects had two contrast-enhanced full-cardiac cycle 4DCT scans: a baseline and a 6-month follow-up scan. CRT response was defined as a reduction in CT-derived end-systolic volume ≥15%. Eight LV features derived from the baseline scans were used to train a support vector machine (SVM) via a bagging approach. An LPS map over the LV was created for each subject as a linear combination of the SVM feature weights and the subject's own feature vector. Performance for distinguishing responders was performed on the original 82 subjects. Results: Fifty-two (63%) subjects were responders. Subjects with an LPS ≤ Q1 (lower-quartile) had a posttest probability of responding of 14% (3/21), while subjects with an LPS ≥ Q3 (upper-quartile) had a posttest probability of responding of 90% (19/21). Subjects with Q1 < LPS < Q3 had a posttest probability of responding that was essentially unchanged from the pretest probability (75% vs 63%, p=0.2). An LPS threshold that maximized the geometric mean of true-negative and true-positive rates identified 26/30 of the non-responders. The AUC of the ROC curve for identifying responders with an LPS threshold was 87%. Conclusions: An LPS map was defined using 4DCT-derived features of LV mechanics. The LPS correlated with CRT response, reclassifying 25% of the subjects into low-probability of response, 25% into high-probability of response, and 50% unchanged. These encouraging results highlight the potential utility of 4DCT in guiding patient selection for CRT. The present findings need verification in larger independent data sets and prospective trials.